Market Research Logo

Global Osteoarthritis Pain Market 2016-2020

About the Osteoarthritis Pain Drugs Market

Osteoarthritis, the most common type of arthritis, is a leading cause of disability. It is a chronic, progressive degenerative joint disease, which is characterized by gradual destruction of the articular cartilage, hypertrophy of the bone margins, and a series of biochemical and morphological changes in the synovial membrane and joint capsule. This results in pain and loss of movement. It is also known as degenerative joint disease, hypertrophic arthritis, and degenerative arthritis, and is most commonly prevalent in older (above 60 years of age) and middle-aged people (between 40-59 years of age). The exact etiology of osteoarthritis is not well understood, but is believed to be an outcome of mechanical and molecular events in the affected joint. Increasing age, obesity, overuse of the joint, weak thigh muscles, and genetics are some of the common risk factors. Treatment is given depending upon the affected joint, including the hand, wrist, neck, back, knee, and hip, and involves medication and exercise.

Technavio’s analysts forecast the global osteoarthritis pain drugs market to grow at a CAGR of 8.38% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global osteoarthritis pain drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat osteoarthritis pain. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Osteoarthritis Pain Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Abbott Laboratories
  • Johnson & Johnson
  • Novartis International
  • Pfizer
Other prominent vendors
  • AbbVie
  • Abiogen Pharma
  • Afferent Pharmaceuticals
  • Astellas Pharma
  • BioDelivery Sciences International
  • Crystal Genomics
  • Cytori Therapeutics
  • Daiichi Sankyo
  • Eli Lilly
  • Endo Pharmaceuticals Holdings
  • Horizon Pharma
  • iCeutica
  • Iroko Pharmaceuticals
  • Merck
  • Nuvo Research
  • Regeneron Pharmaceuticals
  • Sanofi
  • SantoSolve
  • Techfields Pharma
  • Winston Pharmaceuticals
  • Yooyoung Pharmaceutical
  • Zynerba Pharmaceuticals
Market driver
  • Significant unmet medical needs
  • For a full, detailed list, view our report
Market challenge
  • Preference for alternative therapies
  • For a full, detailed list, view our report
Market trend
  • Emergence of new treatments
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Osteoarthritis Pain Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the Global Osteoarthritis Pain Drugs Market: Abbott Laboratories, Johnson & Johnson, Novartis International, and Pfizer.

Other Prominent Vendors in the market are: AbbVie, Abiogen Pharma, Afferent Pharmaceuticals, Astellas Pharma, BioDelivery Sciences International, CrystalGenomics, Cytori Therapeutics, Daiichi Sankyo, Eli Lilly, Endo Pharmaceuticals Holdings, Horizon Pharma, iCeutica, Iroko Pharmaceuticals, Merck, Nuvo Research, Regeneron Pharmaceuticals, Sanofi, SantoSolve, Techfields Pharma, Winston Pharmaceuticals, Yooyoung Pharmaceutical, and Zynerba Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “A key trend that will boost market growth is the emergence of new treatments. Cardax, a development stage life sciences company, is developing astaxanthin therapies for osteoarthritis treatment. The therapy is expected to fulfil large unmet medical needs in the market. Moreover, Arthritis Research UK is conducting studies to develop new treatments for osteoarthritis. One such study is the arcOGEN study, where the genes involved in osteoarthritis are being investigated, and early trials of stem-cell research are done to help in cartilage regrowth.”

According to the report, a key driver of market growth is the high numbers of unmet medical needs. There are a number of unmet medical needs in this market due to the chronic nature of osteoarthritis and the absence of curative therapies. With drugs such as NSAID's, simple analgesics, corticosteroids, and opioids proving effective for individuals with early-to-mid stages of osteoarthritis pain, the competition in the market is strong. However, these options do not provide adequate pain relief in the late stages of osteoarthritis. Ultimately, effective treatment of osteoarthritis pain requires an improved anti-inflammatory molecule, which gives reason for R&D to develop new drugs with better MOA and minimal adverse effects. Thus, absence of effective and safe long-term treatment for creates numerous opportunities for pharmaceutical companies.

Further, the report states that one challenge that could restrict market growth is the consumer’s preference for alternate therapies.

Companies Mentioned

Abbott Laboratories, Johnson & Johnson, Novartis International, Pfizer, AbbVie, Abiogen Pharma, Afferent Pharmaceuticals, Astellas Pharma, BioDelivery Sciences International, CrystalGenomics, Cytori Therapeutics, Daiichi Sankyo, Eli Lilly, Endo Pharmaceuticals Holdings, Horizon Pharma, iCeutica, Iroko Pharmaceuticals, Merck, Nuvo Research, Regeneron Pharmaceuticals, Sanofi, SantoSolve, Techfields Pharma, Winston Pharmaceuticals, Yooyoung Pharmaceutical, Zynerba Pharmaceuticals.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Assumptions
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Key buying criteria
      • Table Key buying criteria
  • Disease overview
    • Understanding osteoarthritis
      • Table Types of osteoarthritis
    • Etiology and pathophysiology
      • Table Etiology and pathophysiology of osteoarthritis
    • Risk factors
    • Signs and symptoms
      • Table Signs and symptoms of osteoarthritis
    • Diagnosis
      • Table Diagnostic test for osteoarthritis
    • Disease management
      • Table Treatment options for osteoarthritis
      • Table Non-pharmacological therapies used for osteoarthritis
      • Table Pharmacotherapy therapy for osteoarthritis
    • Surgical treatment
      • Table Surgical treatment
    • Epidemiology
    • Economic burden of osteoarthritis
      • Table Economic burden of osteoarthritis
      • Table Distribution of direct costs of osteoarthritis
      • Table Cost analysis of treatment for individuals with osteoarthritis
  • Pipeline portfolio
    • Table Pipeline molecules for osteoarthritis pain
    • Information on pipeline candidates
      • Ampion
    • Tanezumab
    • Zilretta (FX006)
    • Fasinumab
    • IP 880
    • SoluMatrix Naproxen
    • ABT-981
    • AF-219
    • ASP7962
  • Osteoarthritis pain drugs: Clinical trials
    • Table Osteoarthritis clinical trials by development phase
    • Table Share of Phase I, II, and III pipeline candidates in osteoarthritis pain drugs market
    • Table Osteoarthritis clinical trials by trial status
  • Opportunities for research in osteoarthritis
    • Table Highlights of osteoarthritis research opportunities:
    • Gaps between current research and possible research issues
    • Challenges for vendors involved in osteoarthritis drug development
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global osteoarthritis pain drugs market 2015-2020 ($ billions)
      • Table Current opportunities of osteoarthritis industry
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Table Global osteoarthritis pain drugs market segmentation by drug class
    • NSAIDs
      • Table Some NSAIDs used to treat osteoarthritis pain
    • Opioids
    • Viscosupplements
    • Corticosteroids
    • Others
      • Table Global osteoarthritis pain drugs market shares by drug class 2015
      • Table Global osteoarthritis pain drugs market segmentation by drug class 2015-2020 ($ billions)
      • Table Global osteoarthritis pain drugs market segmentation by drug class 2015-2020 percentage)
      • Table Global osteoarthritis pain drugs market 2015-2020
      • Table YoY growth rate of global osteoarthritis pain drugs market segments 2015-2020
    • Global NSAIDs market
      • Table Global NSAIDs market 2015-2020 ($ billions)
    • Global opioids market
      • Table Global opioids market 2015-2020 ($ billions)
    • Global viscosupplements market
      • Table Global viscosupplements market 2015-2020 ($ billions)
    • Global corticosteroids market
      • Table Global corticosteroids market 2015-2020 ($ billions)
  • Market segmentation by ROA
    • Table Global osteoarthritis pain drugs market segmentation by ROA
    • Oral
    • Parenteral
    • Topical
      • Table Global osteoarthritis pain drugs market segmentation by ROA 2015
  • Market segmentation by dosage form
    • Table Global osteoarthritis pain drugs market segmentation by dosage form
    • Solid
    • Liquid
    • Semi-solid
      • Table Global osteoarthritis pain drugs market segmentation by ROA 2015
  • Geographical segmentation
    • Table Global osteoarthritis pain drugs market by geographical segmentation 2015
    • Table Global osteoarthritis pain drugs market revenue by geography 2015-2020 ($ billions)
    • Table Global osteoarthritis pain drugs market revenue by geography 2015-2020
    • Table Global osteoarthritis pain drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
    • Osteoarthritis pain drugs market in Americas
      • Table Osteoarthritis pain drugs market in Americas 2015-2020 ($ billions)
      • Table Osteoarthritis pain drugs market in Americas 2015
    • Osteoarthritis pain drugs market in US
      • Table Osteoarthritis pain drugs market in US 2015-2020 ($ billions)
    • Osteoarthritis pain drugs market in EMEA
      • Table Osteoarthritis pain drugs market in EMEA 2015-2020 ($ billions)
    • Osteoarthritis pain drugs market in APAC
      • Table Osteoarthritis pain drugs market in APAC 2015-2020 ($ billions)
  • Market drivers
    • Significant unmet medical needs
      • Table Unmet medical needs with current osteoarthritis pain treatments
    • Promising drug pipeline
    • Increase in prevalence of osteoarthritis and obesity
      • Table Prevalence of osteoarthritis in 2012 and 2022 (millions)
      • Table Average annual prevalence of osteoarthritis in US
      • Table Incidence of osteoarthritis in overweight and normal weight individuals 2013
      • Table Worldwide estimated osteoarthritis population growth 2010-2020
      • Table Population aged 60 years and over: World, developed, and developing regions (millions)
      • Table Expected growth of older population in US 2010-2050
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Preference for alternative therapies
      • Table Alternative therapies for osteoarthritis pain
      • Table Use of CAM therapies among individuals in US
    • Loss of patent exclusivity of branded therapies
    • Adverse effects of drugs
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Emergence of new treatments
      • Table Future therapeutics in osteoarthritis pain treatment
    • Use of off-label drugs
    • Strategic alliances
  • Vendor landscape
    • Competitive scenario
    • Abbott Laboratories
      • Table Key takeaways
    • Johnson & Johnson
      • Table Key takeaways
    • Novartis
      • Table Novartis: YoY revenue and growth rate of Voltaren 2013-2015 ($ millions)
      • Table Key takeaways
    • Pfizer
      • Table Pfizer: YoY revenue and growth rate of Celebrex 2013-2015 ($ millions)
      • Table Pfizer: Geographical segmentation of Celebrex 2015
      • Table Key takeaways
    • Other prominent vendors
  • Upcoming vendors with novel approaches
    • Ampio Pharmaceuticals
    • Flexion Therapeutics
      • Table Flexion Therapeutics: Pipeline products
    • Kitov Pharmaceuticals
      • Table Kitov Pharmaceuticals: Pipeline products
      • Table Osteoarthritis pain market size model
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report